
    
      Amendment 2 of the study Protocol added a third part (Part 3) to the study. The revised
      Official Title for the Protocol is:

      "A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose, and Food Effect Study to Assess
      the Safety, Tolerability, Ventricular Repolarization, and Pharmacokinetics of S-648414 in
      Healthy Adult Study Participants (Part 1); A Phase 1, Randomized, Double-Blind,
      Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of
      S-648414 and A Drug-Drug Interaction Study with the CYP3A Substrate, Midazolam, in Healthy
      Adult Study Participants (Part 2); and A Phase 1 Open-Label Study to Assess the Effect of
      S-648414 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the
      Pharmacokinetics of S-648414 in Healthy Adult Study Participants (Part 3)"
    
  